Journal
NPJ PRECISION ONCOLOGY
Volume 5, Issue 1, Pages -Publisher
NATURE RESEARCH
DOI: 10.1038/s41698-021-00168-1
Keywords
-
Categories
Ask authors/readers for more resources
This study focuses on the use of patient-derived organoids (PDOs) as a potential predictive biomarker in the treatment of cancer patients, emphasizing the importance of individualized tumor response testing.
Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available